Susan Fox

Susan Fox, PhD, ChB, MB

Translational studies of new treatments for movement disorders, including phase II and phase IIII clinical studies.
Neuropharmacology. 2017 Nov 29;:
Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM
Mov Disord. 2017 Nov 13;:
Wagle Shukla A, Fox S
Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380
Li MH, Mestre TA, Fox SH, Taati B
Semin Neurol. 2017 Apr;37(2):147-157
Freitas ME, Hess CW, Fox SH
ACS Chem Neurosci. 2017 May 01;:
Huot P, Sgambato-Faure V, Fox SH, McCreary AC
Br J Haematol. 2017 Apr 25;:
Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A
Mov Disord. 2017 Mar 30;:
Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J
Curr Neurol Neurosci Rep. 2017 Jan;17(1):3
Lim SY, Tan AH, Fox SH, Evans AH, Low SC
JAMA Neurol. 2016 Dec 12;:
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R
Cutis. 2016 Oct;98(4):E10-E12
Fox SH, Elston DM

Pages